TAK News and Press, Takeda Pharmaceutical Company Limited American Depositary Shares From 01/29/26

Nomura Research Institute Ltd. ADR (NRILY) is expected to report $0.33 for Q3 2026 Arthur J. Gallagher & Co. (AJG) is expected to report $2.35 for Q4 2025 STMicroelectronics N.V. (STM) is expected to report $0.27 for Q4 2025 Middlefield Banc Corp. (MBCN) is expected to report $0.6...

2026-01-29 01:51:15 ET More on Takeda Pharmaceutical Takeda Pharmaceutical Company Limited (TAK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Takeda Pharmaceutical Company Limited (TAK) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slide...

Year-to-Date Revenue Declined by 2.8% at Constant Exchange Rate (CER), 3.3% at Actual Exchange Rates (AER); Impact of VYVANSE ® Generics is Tapering Off Core Operating Profit Declined by 3.4% at both CER and AER Year to Date Reported Operating Prof...

2026-01-28 11:20:11 ET More on Takeda Pharmaceutical Takeda Pharmaceutical Company Limited (TAK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Takeda Pharmaceutical Company Limited (TAK) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slide...

− GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with Less Than or Equal to 2 µg/mL IgA in a 10% Solution is Now Available by Prescription for Intravenous or Subcutaneous Use in People Aged Two and Older with Primary Immunodeficiency 1 Takeda ( ...

SAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the appointment of John McAdory as Executive Vice President of Str...

2026-01-13 00:45:58 ET Takeda Pharmaceutical Company Limited (TAK) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 8:15 PM EST... Read the full article on Seeking Alpha For further details see: Takeda Pharmaceutical Company Limited (TAK) Presents at 44th Annua...

2026-01-08 09:06:10 ET More on Halozyme Therapeutics, Takeda Pharmaceutical Halozyme's Elektrofi Deal: Site-Of-Care Optionality (Rating Upgrade) Takeda: Lack Of Realistic Upside In Japanese Pharma Halozyme Therapeutics, Inc. (HALO) Presents at Evercore 8th Annual Hea...

Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Prov...

2025-12-30 09:02:32 ET More related stories Meta: The AI Revenue Leader Nobody Is Talking About Meta: The Company Benefiting From AI Right Now Novo Nordisk: The Real Comeback Starts Now With The Wegovy Pill Takeda, XOMA ink new royalty agreement; amend existi...